Originally established in 2001 as a private biotech company in South San Francisco, Rinat was acquired by Pfizer in 2006 and is operated as an independent biotechnology unit within Pfizer's Worldwide R&D group. This model allows Rinat to maintain the unique culture and scientific environment of a small company while exploiting the world-class capabilities and resources of the broader Pfizer R&D organization. Rinat focuses on antibody-based therapeutics across all disease areas of interest to Pfizer. Rinat researchers couple the latest scientific advancements in human biology with state of the art protein engineering technology platforms to build a premier pipeline. Rinat has also established a group of leading geneticists and computational scientists who leverage novel approaches in genomics to discover and aid in the development of the pipeline. Scientists at Rinat are interested in working with partners who have novel therapeutic approaches or targets, as well as with those who have distinctive technology platforms that can augment Rinat's expertise in converting validated therapeutic targets into novel protein-based therapeutics. Rinat is interested in partnering in oncology and immunology indications, with an emphasis on antibody-based therapies that are immunomodulatory, including those that directly engage or impact T-cell function.
R & D Brochure
Understand what R&D is looking for in an early stage opportunity.
